Nigeria's NAFDAC seeks stiffer penalties for fake drug dealers

28 October 2009

Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) yesterday called for the enactment of la aw prescribing stiffer penalties for drug counterfeiters. It asked the nation to emulate China's approach to the battle against fake drugs, reports the local Vanguard newspaper.

South-East Zonal Director of NAFDAC Festus Anumba, who made the call in Enugu, said the incidence of drug faking was addressed by the Asian country through imposition of stiff penalties on offenders. He called on the National Assembly to consider a review of the laws on counterfeit products, insisting that the producers and importers of fake and sub-standard drugs would continue to be tackled by NAFDAC with all the resources at its disposal.

Mr Anumba stated that the law on fake and sub-standard drugs, as currently constituted, was not commensurate with the offence, adding that many of those who were sanctioned in the past have been caught engaging in the illicit business.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics